← Back to Search

Monoclonal Antibodies

131 I-8H9 for Peritoneal Neoplasm

Phase 1
Waitlist Available
Led By Shakeel Modak, MD
Research Sponsored by Y-mAbs Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial will test the safety of a new antibody medicine injected into the abdominal cavity to treat certain tumors, and if it has any effects, good or bad.

Eligible Conditions
  • Peritoneal Neoplasm

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Define the toxicity of 131I-8H9 administered intraperitoneally.
Secondary outcome measures
Assess pharmacokinetics for 131I-8H9 administered intraperitoneally
Assess response of DSRCT and other solid tumors to 131 I-8H9 administered intraperitoneally
Define maximal tolerated dose (MTD) of 131I-8H9 administered intraperitoneally

Trial Design

1Treatment groups
Experimental Treatment
Group I: 131 I-8H9Experimental Treatment1 Intervention
This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.

Find a Location

Who is running the clinical trial?

Y-mAbs TherapeuticsLead Sponsor
25 Previous Clinical Trials
1,503 Total Patients Enrolled
Shakeel Modak, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
9 Previous Clinical Trials
330 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum
2010. "Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01099644.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top